Eventide Asset Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Eventide Asset Management’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-270,000	Closed	-$18M	–	154
2018 Q1	$18M	Sell	270,000 -54,000	-17%	-$3.12M	0.84%	42
2017 Q4	$16.7M	Hold	324,000	–	–	0.87%	44
2017 Q3	$28.9M	Buy	324,000 +174,000	+116%	+$13.2M	1.64%	21
2017 Q2	$8.96M	Hold	150,000	–	–	0.56%	52
2017 Q1	$8M	Hold	150,000	–	–	0.53%	54
2016 Q4	$7.49M	Hold	150,000	–	–	0.49%	59
2016 Q3	$9.01M	Hold	150,000	–	–	0.55%	52
2016 Q2	$7.67M	Hold	150,000	–	–	0.47%	59
2016 Q1	$4.43M	Hold	150,000	–	–	0.25%	81
2015 Q4	$6.8M	Buy	150,000 +101,000	+206%	+$5.29M	0.34%	71
2015 Q3	$2.04M	Buy	49,000 +10,800	+28%	+$564K	0.12%	99
2015 Q2	$2.3M	Buy	+38,200	New	+$2.53M	0.12%	95

Other funds holding ONCE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Eventide Asset Management's ONCE Position: Q2 2018 in Review

Eventide Asset Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2018, closing a stake of 270,000 shares — an estimated $18M sold.

Eventide Asset Management first reported a position in ONCE in Q2 2015 and held it in 12 quarters. The position peaked at $28.9M in Q3 2017. 172 funds tracked by Wall St. Rank hold ONCE as of Q2 2018.

Eventide Asset Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Eventide Asset Management sold 270,000 Spark Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $18M.
Eventide Asset Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 12 quarters.
Eventide Asset Management's Spark Therapeutics, Inc. Common Stock position peaked at $28.9M in Q3 2017.
172 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Eventide Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.